Current pharmacological management in Juvenile Huntington's disease

Lisa Robertson, Helen Santini, Kirsty L. O'Donovan, Ferdinando Squitieri, Roger A. Barker, Maria Rakowicz, G. Bernhard Landwehrmeyer, Oliver Quarrell

Research output: Contribution to journalArticle

Abstract

Background: The clinical presentation of Juvenile Huntington's Disease (JHD) can be very different from adultonset HD with little evidence to guide symptomatic management. Aim: To survey the current use of pharmacological treatments for JHD. Methods: Patients were identified through the HD Association, Hospital Doctors and the European Huntington's Disease Network REGISTRY study. Results: The most commonly prescribed agents were anti-psychotics (24/45), anti-depressants (17/45) and antiparkinsonian medications (15/45). 5 patients were taking more than 8 medications. Conclusions: The most commonly prescribed group of medication was the anti-psychotic. Many patients were on multiple therapies, highlighting the need to rationalise medications.

Original languageEnglish
Article numberecurrents.RRN1304
JournalPLoS Currents
DOIs
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Fingerprint Dive into the research topics of 'Current pharmacological management in Juvenile Huntington's disease'. Together they form a unique fingerprint.

  • Cite this

    Robertson, L., Santini, H., O'Donovan, K. L., Squitieri, F., Barker, R. A., Rakowicz, M., Landwehrmeyer, G. B., & Quarrell, O. (2012). Current pharmacological management in Juvenile Huntington's disease. PLoS Currents, [ecurrents.RRN1304]. https://doi.org/10.1371/currents.RRN1304